

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 10, 2020

Christopher C. Schreiber Executive Chairman of the Board Akers Biosciences, Inc. 201 Grove Road Thorofare, New Jersey 08086

Re: Akers Biosciences, Inc.

Definitive Proxy Statement on Schedule 14A

Filed July 29, 2020

Preliminary Proxy Statement on Schedule 14A

As Amended July 23, 2020

File No. 001-36268

Dear Mr. Schreiber:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Rick Werner, Esq.